Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 4:04 pm Purchase | 2026-03-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | BIOTECHNOLOGY VALUE FUND L P | 2,347,845 9.990% | 443,588 (+23.29%) | Filing History |
| 2026-05-15 10:31 am Purchase | 2026-03-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Caligan Partners LP | 1,635,023 7.200% | 753,490 (+85.47%) | Filing History |
| 2026-05-15 10:06 am Purchase | 2026-03-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | T. Rowe Price Investment Management, Inc. | 2,162,684 9.500% | 2,162,684 (New Position) | Filing History |
| 2026-05-15 08:15 am Purchase | 2026-03-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Avoro Capital Advisors LLC | 1,410,000 5.750% | 1,410,000 (New Position) | Filing History |
| 2026-05-14 4:09 pm Purchase | 2026-03-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Affinity Asset Advisors, LLC | 1,340,840 5.500% | 289,786 (+27.57%) | Filing History |
| 2026-05-12 6:09 pm Purchase | 2026-05-05 | 13G | AVALO THERAPEUTICS INC PAR AVTX | TCG Crossover GP II, LLC | 3,017,120 7.900% | 3,017,120 (New Position) | Filing History |
| 2026-05-06 11:00 am Purchase | 2026-03-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | FMR LLC | 2,879,481 12.600% | 753,662 (+35.45%) | Filing History |
| 2026-04-01 1:02 pm Purchase | 2026-03-26 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Logos Global Management LP | 1,285,000 5.600% | 1,285,000 (New Position) | Filing History |
| 2026-03-06 10:05 am Purchase | 2026-02-27 | 13G | AVALO THERAPEUTICS INC PAR AVTX | FMR LLC | 2,125,819 11.500% | 2,125,819 (New Position) | Filing History |
| 2026-02-24 4:48 pm Purchase | 2026-02-17 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Millennium Management LLC | 934,429 5.000% | 47,155 (+5.31%) | Filing History |
| 2026-02-17 6:13 pm Purchase | 2025-12-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | ORBIMED ADVISORS LLC | 1,187,300 6.400% | 220,300 (+22.78%) | Filing History |
| 2026-02-17 5:00 pm Purchase | 2025-12-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Caligan Partners LP | 881,533 4.900% | 48,200 (+5.78%) | Filing History |
| 2026-02-17 4:33 pm Sale | 2025-12-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Point72 Asset Management, L.P. | 627,502 3.500% | -426,481 (-40.46%) | Filing History |
| 2026-02-17 4:21 pm Purchase | 2025-12-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | RA Capital Management, L.P. | 1,939,065 9.900% | 552,898 (+39.89%) | Filing History |
| 2026-02-17 4:11 pm Sale | 2026-02-10 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Millennium Management LLC | 887,274 4.800% | -19,488 (-2.15%) | Filing History |
| 2026-02-17 4:07 pm Purchase | 2025-12-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | BIOTECHNOLOGY VALUE FUND L P | 1,904,257 9.990% | 446,106 (+30.59%) | Filing History |
| 2026-02-17 06:57 am Sale | 2025-12-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | BALYASNY ASSET MANAGEMENT L.P. | 439,312 2.420% | -378,124 (-46.26%) | Filing History |
| 2026-02-10 4:07 pm Purchase | 2026-02-03 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Millennium Management LLC | 906,762 4.900% | 964 (+0.11%) | Filing History |
| 2026-02-10 11:36 am Sale | 2025-12-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | SilverArc Capital Management, LLC | 524,436 2.830% | -196,486 (-27.25%) | Filing History |
| 2026-02-03 5:19 pm Purchase | 2026-01-28 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Millennium Management LLC | 905,798 4.900% | 905,798 (New Position) | Filing History |